Natural products (NPs) often serve as a rational starting point for drug development as they commonly show intriguing biological activities based on their complex chemical scaffolds optimized during evolutionary processes. The evolving viral pandemics such as the COVID-19 disease or swine flu and the progressive spread of antibacterial resistances-for example the propagation of multidrug resistant tuberculosis-led to an increased recurrence in natural product research to find promising starting points for the drug discovery pipelines. Besides the evaluation of already described NPs, identification and characterization of novel NPs is of high importance to develop new potential medicines. Among the NPs, bacterial secondary metabolites have already for a century greatly contributed to the stream of natural product based drug leads, especially in antiinfective research and oncology. Myxobacteria, a phylum of ecologically diverse Deltaproteobacteria, are an especially prolific source of such structurally new NPs. They are known to exhibit a broad range of potent antimicrobial, cytotoxic and anti-parasitic activities. Previously uncultured myxobacterial strains, especially those that show significant phylogenetic distance from well-described genera, have proven to be a fruitful source of novel NPs featuring intriguing chemistry and biological activities. As part of our continuous screening efforts of novel myxobacterial strains for yet undescribed NPs, Sandaracinus defensii MSr10575 gained our attention. The only described member of the Sandaracinaceae family so far is S. amylolyticus NOSO-4 T , which was investigated on the genomic level for its starch degrading properties with emphasis on αamylases. Secondary metabolome screening of S. amylolyticus NOSO-4 T furthermore led to the isolation of two prenyl indols (indiacen A and B) in a bioactivity-guided isolation approach. These secondary metabolites were found to exhibit both antibacterial and antifungal properties. Production of indiacen A and B was also observed in S. defensii MSr10575 in a comparative study between supercritical fluid and conventional extraction, where we additionally detected myxochelin A and terrestribisamid A in the strain's extracts and characterized a group of plasmid-encoded nonribosomal peptidepolyketide (NRPS-PKS) hybrids after activation of their underlying biosynthetic machinery, the sandarazols. Myxobacterial terpenoids such as the indiacens are of special interest, as they are significantly underrepresented within the known myxobacterial NPs, despite their biosynthetic gene clusters (BGCs) being not particularly rare. Besides some small terpenoids, such as geosmin and germacradienol -which were first discovered and isolated from actinobacteria-only few myxobacterial terpenes, such as salimyxin, cystodienoic acid, enhygromic acid or the aurachins, were described. Among those, only the strongly bioactive aurachins belong to the class of alkaloid terpenoids, making the sandacrabins-